## Ben O'Leary

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2918484/publications.pdf

Version: 2024-02-01

22

687363 2,613 21 13 h-index citations papers

g-index 22 22 4358 docs citations times ranked citing authors all docs

752698

20

#	Article	IF	CITATIONS
1	Treating cancer with selective CDK4/6 inhibitors. Nature Reviews Clinical Oncology, 2016, 13, 417-430.	27.6	806
2	Plasma <i>ESR1</i> Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer. Journal of Clinical Oncology, 2016, 34, 2961-2968.	1.6	573
3	The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. Cancer Discovery, 2018, 8, 1390-1403.	9.4	397
4	Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nature Communications, 2018, 9, 896.	12.8	305
5	Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. Annals of Oncology, 2018, 29, 145-153.	1.2	114
6	Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. Clinical Cancer Research, 2020, 26, 608-622.	7.0	71
7	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2â <sup>-</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. Clinical Cancer Research, 2022, 28, 3433-3442.	7.0	65
8	Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 309-317.	6.3	60
9	Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. Clinical Chemistry, 2019, 65, 1405-1413.	3.2	53
10	Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. Clinical Chemistry, 2018, 64, 1626-1635.	3.2	46
11	Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer. PLoS ONE, 2016, 11, e0165023.	2.5	29
12	ESR1 mutations in metastatic lobular breast cancer patients. Npj Breast Cancer, 2019, 5, 9.	<b>5.</b> 2	26
13	Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and <i>ESR1</i> mutations (mus) in circulating tumor DNA (ctDNA) Journal of Clinical Oncology, 2016, 34, 512-512.	1.6	17
14	Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant Journal of Clinical Oncology, 2018, 36, 1001-1001.	1.6	11
15	Craniospinal irradiation with concomitant and adjuvant temozolomideâ€"a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. Journal of Neuro-Oncology, 2016, 127, 295-302.	2.9	8
16	Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer. Oncotarget, 2018, 9, 12812-12824.	1.8	8
17	Genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced breast cancer in the PALOMA-3 trial Journal of Clinical Oncology, 2019, 37, 1010-1010.	1.6	8
18	Predicting sensitivity to palbociclib with early circulating tumor DNA dynamics in the PALOMA-3 trial Journal of Clinical Oncology, 2017, 35, 1018-1018.	1.6	6

#	Article	IF	CITATIONS
19	COVID-19: A Catalyst for Change for UK Clinical Oncology. International Journal of Radiation Oncology Biology Physics, 2020, 108, 462-465.	0.8	5
20	Recalibrating emergency care in the UK: pulling our weight. Lancet Oncology, The, 2015, 16, e195.	10.7	1
21	Abstract LB-069: ESR1 mutations in circulating tumour DNA predict outcome to endocrine treatment in patients with estrogen receptor positive advanced breast cancer; analysis of 521 patients in the SoFEA and PALOMA3 trials., 2016,,.		1